External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>Superiority in PFS of zanubrutinib vs ibrutinib in r/r CLL. BeiGene announced superiority in PFS of BRUKINSA (zanubrutinib) vs ibrutinib in the final PFS analysis of the global Ph3 ALPINE trial in patients with r/r CLL, as assessed by both an independent review committee (IRC) and investigator.</li><li>In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and Australia (9%).</li><li>The detailed data will be disclosed at an upcoming medical conference. Zanubrutinib has previously demonstrated PFS benefit at the interim analysis of ALPINE trial.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Superiority in PFS of zanubrutinib vs ibrutinib in r/r CLL. BeiGene announced superiority in PFS of BRUKINSA (zanubrutinib) vs ibrutinib in the final PFS analysis of the global Ph3 ALPINE trial in patients with r/r CLL, as assessed by both an independent review committee (IRC) and investigator.In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and Australia (9%).The detailed data will be disclosed at an upcoming medical conference. Zanubrutinib has previously demonstrated PFS benefit at the interim analysis of ALPINE trial.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Superior PFS Vs Ibrutinib

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeOne (ONC US)

BeiGene (BGNE US) – Superior PFS Vs Ibrutinib

In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)